University of Pittsburgh scientists identified lncRNA EPIC1 as a driver of immunotherapy resistance in triple-negative breast cancer (TNBC). EPIC1 suppresses type I interferon responses facilitating tumor immune evasion. Targeting EPIC1 in preclinical models enhanced the efficacy of PD-1 checkpoint inhibitors, offering a promising therapeutic avenue to improve outcomes in this aggressive cancer subtype.